Vasodilators for use in the treatment of a retinal ischemic disorder

Kristian Agmund Haanes; Vadim Fedulov; Lars Edvinsson; Karin Warfwinge

Vasodilators for use in the treatment of a retinal ischemic disorder

Kristian Agmund Haanes (Inventor), Vadim Fedulov (Inventor), Lars Edvinsson (Inventor), Karin Warfwinge (Inventor)

Abstract

The present invention relates to vasodilators for use in the treatment of a retinal ischemic disorder in a mammal by reducing the retinal ischemic damage for both the photoreceptors (A-wave amplitude) and the Muller and ON-bipolar cells (B-wave amplitude) by at least 10%, when measured by Electroretinography in the mammal compared to the ET-1 induced ischemia alone, at day 3 and at day 21 after the ischemic event and the vasodilator is first applied. The vasodilator may preferably be selected from the group consisting of Calcitonin gene-related peptide (CGRP), amylin, adrenomedullin, and calcitonin.

Original language	English
Patent number	EP2019/084442
Country/Territory	Denmark
Publication status	Published - 2024

Access to Document

https://patents.google.com/patent/US20220023389A1/en

Cite this

@misc{2d9f36c1b47841299f3aebf7a965a853,

title = "Vasodilators for use in the treatment of a retinal ischemic disorder",

abstract = "The present invention relates to vasodilators for use in the treatment of a retinal ischemic disorder in a mammal by reducing the retinal ischemic damage for both the photoreceptors (A-wave amplitude) and the Muller and ON-bipolar cells (B-wave amplitude) by at least 10\%, when measured by Electroretinography in the mammal compared to the ET-1 induced ischemia alone, at day 3 and at day 21 after the ischemic event and the vasodilator is first applied. The vasodilator may preferably be selected from the group consisting of Calcitonin gene-related peptide (CGRP), amylin, adrenomedullin, and calcitonin.",

author = "Haanes, \{Kristian Agmund\} and Vadim Fedulov and Lars Edvinsson and Karin Warfwinge",

year = "2024",

language = "English",

type = "Patent",

note = "EP2019/084442",

}

TY - PAT

T1 - Vasodilators for use in the treatment of a retinal ischemic disorder

AU - Haanes, Kristian Agmund

AU - Fedulov, Vadim

AU - Edvinsson, Lars

AU - Warfwinge, Karin

PY - 2024

Y1 - 2024

N2 - The present invention relates to vasodilators for use in the treatment of a retinal ischemic disorder in a mammal by reducing the retinal ischemic damage for both the photoreceptors (A-wave amplitude) and the Muller and ON-bipolar cells (B-wave amplitude) by at least 10%, when measured by Electroretinography in the mammal compared to the ET-1 induced ischemia alone, at day 3 and at day 21 after the ischemic event and the vasodilator is first applied. The vasodilator may preferably be selected from the group consisting of Calcitonin gene-related peptide (CGRP), amylin, adrenomedullin, and calcitonin.

AB - The present invention relates to vasodilators for use in the treatment of a retinal ischemic disorder in a mammal by reducing the retinal ischemic damage for both the photoreceptors (A-wave amplitude) and the Muller and ON-bipolar cells (B-wave amplitude) by at least 10%, when measured by Electroretinography in the mammal compared to the ET-1 induced ischemia alone, at day 3 and at day 21 after the ischemic event and the vasodilator is first applied. The vasodilator may preferably be selected from the group consisting of Calcitonin gene-related peptide (CGRP), amylin, adrenomedullin, and calcitonin.

M3 - Patent

M1 - EP2019/084442

ER -

Vasodilators for use in the treatment of a retinal ischemic disorder

Abstract

Access to Document

Fingerprint

Cite this